Phase II trial of neoadjuvant docetaxel and ZD 1839 (Iressa) [gefitinib] followed by radical prostatectomy in patients with high risk, locally advanced prostate cancer.

Trial Profile

Phase II trial of neoadjuvant docetaxel and ZD 1839 (Iressa) [gefitinib] followed by radical prostatectomy in patients with high risk, locally advanced prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2012

At a glance

  • Drugs Docetaxel; Gefitinib
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Feb 2012 Actual end date 1 Nov 2007 added as reported by ClinicalTrials.gov.
    • 25 Jul 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top